ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • Citrullin-Specific T cell lines
  • citrullinated vimentin
  • citrullinated vimentin and rheumatoid arthritis (RA)
  • citrullination
  • citrullination and dendritic cells
  • citrullination and juvenile arthritis
  • citrullination and osteoclastogenesis
  • citrullination and proteomics
  • citrullination and rheumatoid arthritis
  • citrullination and rheumatoid arthritis (RA)
  • citrulline
  • Citrulline and juvenile idiopathic arthritis (JIA)
  • Citrulline and osteoclastogenesis
  • citrulline and rheumatoid arthritis (RA)
  • Citrulline and systemic lupus erythematosus (SLE)
  • CKD
  • ckd and population studies
  • Claims data and Rheumatoid Arthritis
  • CLASI
  • Classical Monocytes
  • classification criteria
  • classification criteria and autoantibodies
  • classification criteria and clinical practice
  • classification criteria and clinical research
  • classification criteria and cross-sectional studies
  • classification criteria and cutaneous lupus erythematosus
  • classification criteria and dermatomyositis
  • classification criteria and diagnosis
  • classification criteria and diagnostic criteria
  • Classification criteria and fibromyalgia
  • Classification criteria and gout
  • classification criteria and inflammation
  • classification criteria and joint
  • Classification criteria and juvenile idiopathic arthritis (JIA)
  • classification criteria and juvenile spondylarthropathy
  • classification criteria and macrophage activation syndrome
  • classification criteria and microbiome
  • classification criteria and muscle biopsy
  • Classification criteria and myositis
  • classification criteria and non-radiographic
  • classification criteria and performance
  • Classification criteria and polymyalgia rheumatica
  • Classification criteria and polymyalgia rhuematica
  • Classification criteria and psoriatic arthritis
  • classification criteria and race/ethnicity
  • Classification criteria and reactive arthritis
  • classification criteria and resolution of disease
  • Classification criteria and rheumatoid arthritis (RA)
  • classification criteria and risk
  • Classification criteria and scleroderma
  • classification criteria and serologic tests
  • classification criteria and spondylarthritis
  • Classification criteria and spondylarthropathy
  • classification criteria and systemic lupus erythematosus (SLE)
  • Classification criteria and systemic sclerosis
  • classification criteria and ultrasonography
  • classification criteria and vasculitis
  • Clinical
  • Clinical and cohort
  • Clinical and Disease Activity
  • Clinical and IgG4
  • Clinical and Musculoskeletal
  • Clinical and SLE
  • Clinical and spondylarthritis
  • Clinical and systemic lupus erythematosus (SLE)
  • Clinical and tocilizumab
  • Clinical Disease activity
  • Clinical Osteoporosis
  • Clinical outcome and drug safety
  • Clinical outcome and Hispanic patients
  • Clinical outcomes
  • Clinical practice
  • clinical practice and clinical practice guidelines
  • clinical practice and diagnosis
  • clinical practice and diagnostic criteria
  • clinical practice and Disease Activity
  • clinical practice and education
  • clinical practice and genetics
  • clinical practice and inflammation
  • Clinical practice and juvenile idiopathic arthritis (JIA)
  • clinical practice and non-radiographic
  • Clinical practice and osteoarthritis
  • clinical practice and outcome measures
  • Clinical practice and patient outcomes
  • clinical practice and patient questionnaires
  • clinical practice and quality improvement
  • clinical practice and rheumatoid arthritis (RA)
  • clinical practice and serologic tests
  • Clinical practice and spondylarthritis
  • clinical practice and systemic lupus erythematosus (SLE)
  • clinical practice and tofacitinib
  • clinical practice and treatment
  • Clinical practice guidelines
  • clinical practice guidelines and health disparities
  • clinical practice guidelines and Lupus
  • clinical practice guidelines and oral
  • clinical practice guidelines and remission
  • Clinical practice guidelines and systemic sclerosis
  • clinical practice guidelines and treatment
  • clinical practice guidelines and tuberculosis
  • Clinical Predictors
  • clinical remission
  • Clinical Remission and quality of life
  • Clinical research
  • clinical research and biomarkers
  • clinical research and clinical trials
  • clinical research and hypertension
  • Clinical research and immunoglobulin (IG)
  • clinical research and infection
  • clinical research and interferons
  • clinical research and interleukins (IL)
  • clinical research and juvenile idiopathic arthritis (JIA)
  • clinical research and laboratory tests
  • clinical research and osteoarthritis
  • clinical research and outcomes
  • Clinical research and pharmacokinetics
  • Clinical research and psoriatic arthritis
  • Clinical research and quality of care
  • clinical research and rheumatoid arthritis (RA)
  • clinical research and RNA
  • clinical research and scleroderma
  • clinical research and socio-economic inequities
  • clinical research and spondylarthritis
  • clinical research and systemic lupus erythematosus (SLE)
  • clinical research and takayasu arteritis
  • clinical research and uveitis
  • clinical research and vasculitis
  • Clinical research methods
  • clinical research methods and African-Americans
  • clinical research methods and minority
  • Clinical Response
  • Clinical Response and adaptive immunity
  • Clinical Response and ankylosing spondylitis (AS)
  • Clinical Response and axial spondyloarthritis
  • Clinical Response and epidemiologic methods
  • Clinical Response and ethics
  • Clinical Response and ethnic studies
  • Clinical Response and fibromyalgia
  • Clinical Response and MicroRNA
  • Clinical Response and psoriatic arthritis
  • Clinical Response and registries
  • Clinical Response and Rheumatoid Factor
  • Clinical Science
  • clinical skills
  • Clinical Study and ADDRESS II
  • clinical trial
  • clinical trials
  • clinical trials and Autoimmune Skin Disease
  • clinical trials and azathioprine
  • clinical trials and biosimilars
  • Clinical trials and dermatomyositis
  • clinical trials and drug treatment
  • Clinical trials and fibromyalgia
  • clinical trials and glucocorticoids
  • clinical trials and juvenile idiopathic arthritis (JIA)
  • clinical trials and laboratory tests
  • clinical trials and lipids
  • clinical trials and lupus nephritis
  • clinical trials and monoclonal antibodies
  • clinical trials and osteoarthritis
  • clinical trials and osteoporosis
  • clinical trials and outcome measures
  • clinical trials and pain
  • clinical trials and polymyalgia rheumatica
  • clinical trials and psoriasis
  • clinical trials and quality
  • clinical trials and randomized trials
  • clinical trials and registries
  • clinical trials and remission
  • clinical trials and renal disease
  • clinical trials and rheumatic disease
  • Clinical trials and rheumatoid arthritis
  • clinical trials and rheumatoid arthritis (RA)
  • clinical trials and rituximab
  • clinical trials and scleroderma
  • clinical trials and statistical methods
  • clinical trials and systemic lupus erythematosus (SLE)
  • clinical trials and systemic sclerosis
  • clinical trials and thrombosis
  • Clinical trials and tocilizumab
  • clinical trials and treatment
  • clinical trials and ulcers
  • clinical trials and vasculitis
  • Clinically Suspect Arthralgia
  • clinically suspect arthralgia and inflammatory arthritis
  • CLK/DYRK inhibitor
  • Clonal Expansion
  • cluster
  • Cmax
  • CMS
  • CMV
  • cno
  • CNS
  • CNS inflammation
  • CNS Lupus
  • CNS Lupus and autoantibodies
  • CNS Lupus and immunoregulation
  • CNS Lupus and Immunotherapy
  • CNS Lupus and magnetic resonance imaging (MRI)
  • CNS Lupus and SLE
  • First |
  • « Previous Page
  • 8
  • 9
  • 10
  • 11
  • 12
  • [13]
  • 14
  • 15
  • 16
  • 17
  • 18
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology